Related Experiment Video

Updated: Jun 26, 2026

Modeling an Enzyme Active Site using Molecular Visualization Freeware
14:37

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Published on: December 25, 2021

Molecular modeling of human BAD and its interaction with PKAc or PP1c

Jie Yang1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing 210093, PR China. yangjie@nju.edu.cn

Journal of Theoretical Biology
|December 24, 2008
PubMed

Insights

This study reveals the molecular interactions between BAD and its regulatory proteins PKAc and PP1c. Understanding these structural details aids in developing new drugs targeting apoptosis and glycolysis integration.

Area of Science:

  • Molecular Biology
  • Structural Biology
  • Biochemistry

Background:

  • The Bcl-2 antagonist of cell death (BAD) protein plays a crucial role in regulating apoptosis.
  • Understanding the molecular interactions of BAD with its regulatory kinases and phosphatases is essential for cellular regulation.

Purpose of the Study:

  • To elucidate the structural basis of the interaction between BAD and protein kinase A catalytic subunit (PKAc) or protein phosphatase 1 catalytic subunit (PP1c).
  • To identify optimal binding sites and orientations for molecular recognition between BAD and its regulatory partners.

Main Methods:

  • * Construction of human BAD structure.
  • * Computational modeling to determine optimal positions and orientations of amino acid residues in binding sites.
  • * Analysis of interaction interfaces between BAD, PKAc, and PP1c.

Main Results:

  • * Identified specific binding sites on BAD, including N-termini, BH3 domain, and C-termini.
  • * Characterized interaction sites on PKAc and PP1c, involving specific motifs and regions.
  • * Complex models revealed that the BAD BH3 domain interacts with PKAc/PP1c via electrostatic, van der Waals, hydrogen bonds, and salt bridges.

Conclusions:

  • * The study provides novel structural insights into the molecular recognition between BAD and its regulators.
  • * Findings are valuable for developing new therapeutic agents, such as mimetic BH3 peptides.
  • * The research inspires further investigation into the role of BAD complexes in integrating glycolysis and apoptosis.

More Related Videos

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Molecular Models02:00

Molecular Models

Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...